Nanospectra Biosciences
Nanospectra Biosciences is a clinical-stage, privately-held Houston-based nanomedicine company founded in 2002 that develops particle-based therapies for the selective thermal destruction of solid tumors.
- Company typePrivate
- Founded2002
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nanospectra Biosciences does
Nanospectra Biosciences is a privately-held, clinical-stage nanomedicine company founded in 2002 and headquartered in Houston, Texas. The company develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors, leveraging nanoshell-related technology originated by its co-founders Naomi Halas (nanophotonics) and Jennifer West (bioengineering) out of Rice University.
The company's core technology centers on particle-mediated thermal ablation, in which systemically or locally delivered particles accumulate preferentially in tumor tissue and, upon external energy activation, produce localized heating that destroys malignant cells while sparing surrounding healthy tissue. This positions Nanospectra in the oncology device/drug-combination segment, targeting solid tumor indications.
The business remains pre-commercial, with no disclosed revenue, customers, or pricing models in the available data. Capital formation has been the primary operating signal: the firm has completed multiple exempt offerings and rounds spanning 2010 through March 2023, including a $3 million strategic investment from Sirtex Medical in 2020 and a March 2023 raise of approximately $6 million against a $10 million target. The leadership team is small (1-10 employees) and operating under an interim CEO (David Jorden, also Chairman), consistent with a development-stage organization channeling capital toward clinical and regulatory milestones rather than commercial scaling.
Nanospectra Biosciences firmographics
Firmographics- Name
- Nanospectra Biosciences
- Legal name
- NANOSPECTRA BIOSCIENCES INC
- Website
- https://nanospectra.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nanospectra Biosciences is a clinical-stage, privately-held Houston-based nanomedicine company founded in 2002 that develops particle-based therapies for the selective thermal destruction of solid tumors.
- Ownership category
- akta.pro rank
Nanospectra Biosciences industry classification
Industry- Product category
- Nanomedicine Oncology Therapy
- NAICS
- Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Surgical Oncology (HLAKAFAG)
Keywords
Where Nanospectra Biosciences is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Markets served
Nanospectra Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Nanospectra Biosciences product offering
Product offeringCore offering
Nanospectra Biosciences develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors. The company's nanomedicine platform delivers localized photothermal treatment using targeted nanoparticles activated to ablate malignant tissue while sparing surrounding healthy structures. Its lead program targets solid tumor indications through this minimally invasive, image-guided therapeutic approach.
Differentiator
Problem solved
Functional benefit
Products and services
- Particle-based solid tumor therapy
Companies that use Nanospectra Biosciences
Customer profileIdeal customer profiles1 record
Nanospectra Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nanospectra Biosciences partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights2 records
Nanospectra Biosciences competitors and assessment
Company assessmentDirect peers
- MagForce AG: German company developing NanoTherm, a superparamagnetic iron oxide nanoparticle therapy activated by an alternating magnetic field to thermally ablate solid tumors (notably glioblastoma and prostate cancer). Closest direct peer in nanoparticle-based tumor thermal destruction.
- Nanobiotix: French clinical-stage nanomedicine company developing NBTXR3, hafnium oxide nanoparticles that enhance the efficacy of radiation therapy in solid tumors. Directly comparable nanomedicine oncology platform with similar development-stage profile.
- Celsion Corporation: Clinical-stage oncology company developing ThermoDox, a heat-activated liposomal doxorubicin that releases chemotherapy when tumor tissue is heated. Directly comparable heat-mediated oncology therapeutic platform.
- EDAP TMS: Developer of Focal One and Ablatherm HIFU (high-intensity focused ultrasound) systems for prostate and other tumor ablation. Direct competitor in localized prostate tumor ablation, the same target indication as Nanospectra's lead work.
- Profound Medical: Commercial-stage developer of TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Directly competes with Nanospectra's particle-mediated approach in the focal prostate therapy market.
- Perseon Medical (formerly BSD Medical): Developer of hyperthermia and thermal therapy systems used to heat tumor tissue in combination with radiation or chemotherapy. Direct peer in thermally mediated oncology treatment.
Broad incumbents
- Sirtex Medical: Commercial-stage interventional oncology company selling SIR-Spheres Y-90 microspheres for liver cancer. Existing strategic investor in Nanospectra and broader incumbent in radiation-based locoregional tumor therapy.
- AngioDynamics: Medical device company selling the NanoKnife irreversible electroporation (IRE) system for soft-tissue tumor ablation. Broad incumbent in interventional oncology ablation overlapping Nanospectra's tumor-destruction category.
- Boston Scientific (Interventional Oncology / BTG): Acquired BTG's interventional oncology business (TheraSphere Y-90, embolization). Large incumbent with overlapping capabilities in locoregional tumor therapy, relevant as potential strategic acquirer or partner.
Emerging players
- IceCure Medical: Developer of cryoablation platforms (ProSense) for breast, kidney, lung, and prostate tumors. Emerging competitor in the minimally invasive solid tumor ablation space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Nanospectra Biosciences social profiles
Digital presenceNanospectra Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nanospectra Biosciences leadership team
Management profileNumber of profiles
Profiles4 records
Nanospectra Biosciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nanospectra Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nanospectra Biosciences
What does Nanospectra Biosciences do?
Nanospectra Biosciences develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors. The company's nanomedicine platform delivers localized photothermal treatment using targeted nanoparticles activated to ablate malignant tissue while sparing surrounding healthy structures. Its lead program targets solid tumor indications through this minimally invasive, image-guided therapeutic approach.
Is Nanospectra Biosciences a public or private company?
Nanospectra Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nanospectra Biosciences founded?
Nanospectra Biosciences was founded in 2002. It employs 1 to 10 people.
Where is Nanospectra Biosciences based?
Nanospectra Biosciences is headquartered in Houston, United States, in the North America region.
Who are Nanospectra Biosciences's main competitors?
Direct peers on record are MagForce AG, Nanobiotix, Celsion Corporation, EDAP TMS, Profound Medical and Perseon Medical (formerly BSD Medical). Broad incumbents are Sirtex Medical, AngioDynamics and Boston Scientific (Interventional Oncology / BTG). IceCure Medical is listed as an emerging player.
Does Nanospectra Biosciences have an API?
No public API is recorded for Nanospectra Biosciences.
What industry is Nanospectra Biosciences in?
Nanospectra Biosciences's product category is Nanomedicine Oncology Therapy. Its primary akta.pro industry code is HLAKAFAG, Surgical Oncology. Its NAICS code is 541713 and its SIC code is 2836.